JP2023515199A5 - - Google Patents
Info
- Publication number
- JP2023515199A5 JP2023515199A5 JP2022551584A JP2022551584A JP2023515199A5 JP 2023515199 A5 JP2023515199 A5 JP 2023515199A5 JP 2022551584 A JP2022551584 A JP 2022551584A JP 2022551584 A JP2022551584 A JP 2022551584A JP 2023515199 A5 JP2023515199 A5 JP 2023515199A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- trgv9
- target
- cdr2
- cdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (91)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062982535P | 2020-02-27 | 2020-02-27 | |
| US202062982462P | 2020-02-27 | 2020-02-27 | |
| US202062982492P | 2020-02-27 | 2020-02-27 | |
| US202062982574P | 2020-02-27 | 2020-02-27 | |
| US202062982505P | 2020-02-27 | 2020-02-27 | |
| US202062982478P | 2020-02-27 | 2020-02-27 | |
| US202062982469P | 2020-02-27 | 2020-02-27 | |
| US202062982525P | 2020-02-27 | 2020-02-27 | |
| US202062982602P | 2020-02-27 | 2020-02-27 | |
| US202062982591P | 2020-02-27 | 2020-02-27 | |
| US202062982664P | 2020-02-27 | 2020-02-27 | |
| US202062982548P | 2020-02-27 | 2020-02-27 | |
| US202062982374P | 2020-02-27 | 2020-02-27 | |
| US202062982669P | 2020-02-27 | 2020-02-27 | |
| US62/982,462 | 2020-02-27 | ||
| US62/982,374 | 2020-02-27 | ||
| US62/982,602 | 2020-02-27 | ||
| US62/982,574 | 2020-02-27 | ||
| US62/982,669 | 2020-02-27 | ||
| US62/982,535 | 2020-02-27 | ||
| US62/982,478 | 2020-02-27 | ||
| US62/982,525 | 2020-02-27 | ||
| US62/982,591 | 2020-02-27 | ||
| US62/982,548 | 2020-02-27 | ||
| US62/982,469 | 2020-02-27 | ||
| US62/982,664 | 2020-02-27 | ||
| US62/982,492 | 2020-02-27 | ||
| US62/982,505 | 2020-02-27 | ||
| US202062989024P | 2020-03-13 | 2020-03-13 | |
| US202062989006P | 2020-03-13 | 2020-03-13 | |
| US202062989068P | 2020-03-13 | 2020-03-13 | |
| US202062989052P | 2020-03-13 | 2020-03-13 | |
| US202062989010P | 2020-03-13 | 2020-03-13 | |
| US202062989036P | 2020-03-13 | 2020-03-13 | |
| US202062989002P | 2020-03-13 | 2020-03-13 | |
| US202062989027P | 2020-03-13 | 2020-03-13 | |
| US202062989018P | 2020-03-13 | 2020-03-13 | |
| US202062989045P | 2020-03-13 | 2020-03-13 | |
| US202062989042P | 2020-03-13 | 2020-03-13 | |
| US202062988996P | 2020-03-13 | 2020-03-13 | |
| US202062989057P | 2020-03-13 | 2020-03-13 | |
| US202062989075P | 2020-03-13 | 2020-03-13 | |
| US62/989,045 | 2020-03-13 | ||
| US62/989,036 | 2020-03-13 | ||
| US62/989,006 | 2020-03-13 | ||
| US62/988,996 | 2020-03-13 | ||
| US62/989,018 | 2020-03-13 | ||
| US62/989,042 | 2020-03-13 | ||
| US62/989,068 | 2020-03-13 | ||
| US62/989,027 | 2020-03-13 | ||
| US62/989,052 | 2020-03-13 | ||
| US62/989,075 | 2020-03-13 | ||
| US62/989,002 | 2020-03-13 | ||
| US62/989,024 | 2020-03-13 | ||
| US62/989,010 | 2020-03-13 | ||
| US62/989,057 | 2020-03-13 | ||
| USPCT/US2020/031749 | 2020-05-07 | ||
| PCT/US2020/031749 WO2020227457A1 (en) | 2019-05-08 | 2020-05-07 | Materials and methods for modulating t cell mediated immunity |
| US202063074893P | 2020-09-04 | 2020-09-04 | |
| US202063074839P | 2020-09-04 | 2020-09-04 | |
| US202063074676P | 2020-09-04 | 2020-09-04 | |
| US202063074962P | 2020-09-04 | 2020-09-04 | |
| US202063074759P | 2020-09-04 | 2020-09-04 | |
| US202063074946P | 2020-09-04 | 2020-09-04 | |
| US202063074700P | 2020-09-04 | 2020-09-04 | |
| US202063074937P | 2020-09-04 | 2020-09-04 | |
| US202063074655P | 2020-09-04 | 2020-09-04 | |
| US202063074854P | 2020-09-04 | 2020-09-04 | |
| US202063074749P | 2020-09-04 | 2020-09-04 | |
| US202063074903P | 2020-09-04 | 2020-09-04 | |
| US202063074925P | 2020-09-04 | 2020-09-04 | |
| US202063074735P | 2020-09-04 | 2020-09-04 | |
| US63/074,735 | 2020-09-04 | ||
| US63/074,749 | 2020-09-04 | ||
| US63/074,759 | 2020-09-04 | ||
| US63/074,937 | 2020-09-04 | ||
| US63/074,700 | 2020-09-04 | ||
| US63/074,655 | 2020-09-04 | ||
| US63/074,893 | 2020-09-04 | ||
| US63/074,839 | 2020-09-04 | ||
| US63/074,676 | 2020-09-04 | ||
| US63/074,946 | 2020-09-04 | ||
| US63/074,962 | 2020-09-04 | ||
| US63/074,925 | 2020-09-04 | ||
| US63/074,903 | 2020-09-04 | ||
| US63/074,854 | 2020-09-04 | ||
| US202063112462P | 2020-11-11 | 2020-11-11 | |
| US202063112475P | 2020-11-11 | 2020-11-11 | |
| US63/112,462 | 2020-11-11 | ||
| US63/112,475 | 2020-11-11 | ||
| PCT/US2021/019766 WO2021173896A1 (en) | 2020-02-27 | 2021-02-26 | Materials and methods for modulating an immune response |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023515199A JP2023515199A (ja) | 2023-04-12 |
| JP2023515199A5 true JP2023515199A5 (cg-RX-API-DMAC7.html) | 2024-03-06 |
Family
ID=77492135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022551584A Pending JP2023515199A (ja) | 2020-02-27 | 2021-02-26 | 免疫応答を調節するための材料及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220306739A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023515199A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220147631A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115484981A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021225870A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3173268A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL295897A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022010664A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202144415A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021173896A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10501540B2 (en) | 2014-04-10 | 2019-12-10 | Lava Therapeutics B.V. | Immunoglobulins binding human Vγ9 Vδ2 T cell receptors |
| MX386714B (es) | 2015-01-27 | 2025-03-11 | Lava Therapeutics N V | Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d). |
| JP7457007B2 (ja) | 2018-09-19 | 2024-03-27 | ラヴァ・セラピューティクス・エヌ・ヴイ | 二重作用CD1d免疫グロブリン |
| CN119954959A (zh) | 2019-03-11 | 2025-05-09 | 詹森生物科技公司 | 抗Vβ17/抗CD123双特异性抗体 |
| JP7686571B2 (ja) * | 2019-05-08 | 2025-06-02 | ヤンセン バイオテツク,インコーポレーテツド | T細胞媒介性免疫を調節するための材料及び方法 |
| EP4076526A4 (en) | 2019-12-17 | 2024-07-03 | The Board Of Regents Of The University Of Texas System | Novel ddr1 antibodies and uses thereof |
| CN116323667A (zh) | 2020-07-08 | 2023-06-23 | 拉法医疗股份有限公司 | 结合PSMA和γ-δT细胞受体的抗体 |
| IL301242A (en) * | 2020-09-11 | 2023-05-01 | Janssen Biotech Inc | Multi-specific immune targeting molecules and uses thereof |
| UY39415A (es) | 2020-09-11 | 2022-03-31 | Janssen Biotech Inc | Métodos y composiciones para modular la inmunidad mediada por cadenas beta |
| WO2022056197A1 (en) | 2020-09-11 | 2022-03-17 | Janssen Biotech, Inc. | Immune targeting molecules and uses thereof |
| US12076413B2 (en) | 2020-10-28 | 2024-09-03 | Janssen Biotech, Inc. | Compositions and methods for modulating delta gamma chain mediated immunity |
| WO2022175255A2 (en) | 2021-02-16 | 2022-08-25 | Janssen Pharmaceutica Nv | Trispecific antibody targeting bcma, gprc5d, and cd3 |
| CN120076829A (zh) | 2022-10-18 | 2025-05-30 | 明治制果药业株式会社 | T细胞肿瘤的治疗剂 |
| EP4637822A2 (en) * | 2022-12-23 | 2025-10-29 | The Wistar Institute of Anatomy and Biology | Siglec 9 inhibitors and methods of use thereof for enhancing immunotherapy efficacy |
| AU2024379650A1 (en) * | 2023-11-15 | 2026-06-04 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Trgv9 binding proteins and medical use thereof |
| WO2025220690A1 (ja) * | 2024-04-17 | 2025-10-23 | Meiji Seikaファルマ株式会社 | T細胞腫瘍以外の悪性腫瘍患者に有効な二重特異性抗体 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002351208A1 (en) * | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Antibodies against carbonic anhydrase IX (CA IX) tumor antigen |
| EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| JP2012505654A (ja) * | 2008-10-14 | 2012-03-08 | ヤンセン バイオテツク,インコーポレーテツド | 抗体をヒト化及び親和性成熟する方法 |
| US10501540B2 (en) * | 2014-04-10 | 2019-12-10 | Lava Therapeutics B.V. | Immunoglobulins binding human Vγ9 Vδ2 T cell receptors |
| EP3560955A4 (en) * | 2016-12-26 | 2020-12-23 | Kyowa Kirin Co., Ltd. | ANTIBODIES CAPABLE OF BINDING TO MYELIN OLIGODENDROCYTE GLYCOPROTEIN |
| WO2019147735A1 (en) * | 2018-01-23 | 2019-08-01 | New York University | Antibodies specific to delta 1 chain of t cell receptor |
| BR112020023508A2 (pt) * | 2018-05-24 | 2021-03-30 | Janssen Biotech, Inc. | Anticorpos anti-cd3 e usos dos mesmos |
| JOP20190116A1 (ar) * | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
| JP7686571B2 (ja) * | 2019-05-08 | 2025-06-02 | ヤンセン バイオテツク,インコーポレーテツド | T細胞媒介性免疫を調節するための材料及び方法 |
| PE20231517A1 (es) * | 2020-03-13 | 2023-09-28 | Janssen Biotech Inc | Materiales y metodos para la union de siglec-3/cd33 |
-
2021
- 2021-02-26 CA CA3173268A patent/CA3173268A1/en active Pending
- 2021-02-26 IL IL295897A patent/IL295897A/en unknown
- 2021-02-26 KR KR1020227033246A patent/KR20220147631A/ko not_active Ceased
- 2021-02-26 AU AU2021225870A patent/AU2021225870A1/en not_active Abandoned
- 2021-02-26 CN CN202180031394.5A patent/CN115484981A/zh active Pending
- 2021-02-26 US US17/186,704 patent/US20220306739A1/en active Pending
- 2021-02-26 WO PCT/US2021/019766 patent/WO2021173896A1/en not_active Ceased
- 2021-02-26 MX MX2022010664A patent/MX2022010664A/es unknown
- 2021-02-26 JP JP2022551584A patent/JP2023515199A/ja active Pending
- 2021-02-26 TW TW110107163A patent/TW202144415A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL295897A (en) | Materials and methods for modulating an immune response | |
| JP2023126852A5 (cg-RX-API-DMAC7.html) | ||
| JP2019533450A5 (cg-RX-API-DMAC7.html) | ||
| FI3535392T3 (fi) | Immunologisesti havaittavia solupintavariantteja käytettäväksi soluterapiassa | |
| JP2024506682A5 (cg-RX-API-DMAC7.html) | ||
| US20220403025A1 (en) | Therapeutic uses of anti-tcr delta variable 1 antibodies | |
| EP4265643B1 (en) | Multispecific anti-tcr delta variable 1 antibodies | |
| JP2023537534A5 (cg-RX-API-DMAC7.html) | ||
| JP2004528806A5 (cg-RX-API-DMAC7.html) | ||
| US20210284731A1 (en) | Methods and materials for modulating an immune response | |
| JP2025513879A5 (cg-RX-API-DMAC7.html) | ||
| JP2025517657A5 (cg-RX-API-DMAC7.html) | ||
| JP2023540796A5 (cg-RX-API-DMAC7.html) | ||
| HK40102395A (en) | Multispecific anti-tcr delta variable 1 antibodies | |
| HK40102395B (en) | Multispecific anti-tcr delta variable 1 antibodies | |
| HK40102396A (en) | Multispecific anti-tcr delta variable 1 antibodies | |
| HK40103226A (en) | Multispecific anti-tcr delta variable 1 antibodies | |
| HK40103002A (en) | Multispecific anti-tcr delta variable 1 antibodies | |
| HK40103002B (en) | Multispecific anti-tcr delta variable 1 antibodies | |
| HK40097714A (en) | Multispecific anti-tcr delta variable 1 antibodies | |
| HK40103477A (en) | Multispecific anti-tcr delta variable 1 antibodies | |
| HK40076296B (en) | Multispecific anti-tcr delta variable 1 antibodies | |
| HK40076296A (en) | Multispecific anti-tcr delta variable 1 antibodies | |
| EA048115B1 (ru) | Терапевтическое применение антител к tcr с вариабельной цепью дельта 1 |